• 100+

    The UK’s most active investor in UK university spin-outs

  • £250M

    Over £250m raised; invested into over 100 companies

  • 16 wins

    Award winning manager with track record of delivering returns

  • £1.1Bn

    Part of FTSE 250 sector specialist group with £1.1bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.
Covid-19 Update: We continue to operate as usual, supporting the best of our technology companies. We accept applications by email and are having video updates with investors and advisers. Further details here.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Chloe Richardson
Moray Wright
Kathy Samii
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

Surrey NanoSystems

Surrey NanoSystems has developed technologies that deliver precise, ordered nanomaterial structures for advanced CMOS manufacturing processes at low temperatures. Using this technology, the Company developed super-black coatings, including Vantablack®. Vantablack® is revolutionary in its ability to be applied to light-weight, temperature-sensitive structures, whilst absorbing 99.96% of incident

YASA

YASA has developed revolutionary compact, lightweight and powerful electric motors and controllers. The products enable vehicle hybridization and electrification, especially where there is limited powertrain space. The company supplies custom and off-the-shelf e-motors and controllers to automotive customers from its Oxford headquarters.

PolyProx Therapeutics

PolyProx Therapeutics is a spin out of the Department of Pharmacology at the University of Cambridge,  and is based on over a decade of research and intellectual property from Founder, Professor Laura Itzhaki’s laboratory. Professor Itzhaki is joined at PolyProx Therapeutics by serial Cambridge biotech entrepreneurs Kevin Moulder as Chief Operating Officer and Andrew Sandham

View Portfolio